TLTFF (Theralase Technologies) Total Stockholders Equity : $1.45 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies Total Stockholders Equity?

Theralase Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $1.45 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Theralase Technologies's Book Value per Share for the quarter that ended in Dec. 2024 was $0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Theralase Technologies's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.14.

Theralase Technologies Total Stockholders Equity Historical Data

The historical data trend for Theralase Technologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Total Stockholders Equity Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

7.15

3.96

2.28

1.42

1.45

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															1.42	1.46	1.21	1.58	1.45

Theralase Technologies (OTCPK:TLTFF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Theralase Technologies's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1.451	-	0)	/	247.780
	=	0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Theralase Technologies's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.07	+	0.136)	/	1.451
	=	0.14

Theralase Technologies Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

TTX:Germany TLT:Canada

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.